A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.

Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.

The latest advances in the treatment of Alzheimer’s disease and how Cambridge Cognition are designing and implementing empirically validated and clinically-relevant cognitive tasks to help develop the next generation of Alzheimer’s disease treatments. 

There are presently over 140 drugs being explored as possible treatments for Alzheimer’s Disease (AD) in clinical trials. Of these, nearly 80% are intended to slow the progression of AD. Historically, cholinesterase inhibitor drugs such as galantamine, rivastigmine and donepezil have been approved for treatment of AD. These drugs have been shown to mitigate symptoms of AD, such as memory loss, however they are unable to treat the underlying neurobiological cause of the condition. As such, these drugs do not slow AD progression and are not considered a long-term solution in the battle to end the most common form of neurodegenerative disease.